HRP20182043T1 - Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze - Google Patents

Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze

Info

Publication number
HRP20182043T1
HRP20182043T1 HRP20182043TT HRP20182043T HRP20182043T1 HR P20182043 T1 HRP20182043 T1 HR P20182043T1 HR P20182043T T HRP20182043T T HR P20182043TT HR P20182043 T HRP20182043 T HR P20182043T HR P20182043 T1 HRP20182043 T1 HR P20182043T1
Authority
HR
Croatia
Prior art keywords
enhancing
therapeutic effect
acetylcholinesterase inhibitors
connexin agents
connexin
Prior art date
Application number
HRP20182043TT
Other languages
English (en)
Inventor
Franck Mouthon
Mathieu Charveriat
Original Assignee
Commissariat à l'énergie atomique et aux énergies alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat à l'énergie atomique et aux énergies alternatives filed Critical Commissariat à l'énergie atomique et aux énergies alternatives
Publication of HRP20182043T1 publication Critical patent/HRP20182043T1/hr
Publication of HRP20182043T8 publication Critical patent/HRP20182043T8/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20182043TT 2011-10-31 2018-12-05 Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze HRP20182043T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306407.5A EP2586436A1 (en) 2011-10-31 2011-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
EP12778762.0A EP2773337B1 (en) 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
PCT/EP2012/071631 WO2013064579A1 (en) 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
HRP20182043T1 true HRP20182043T1 (hr) 2019-04-19
HRP20182043T8 HRP20182043T8 (hr) 2019-06-14

Family

ID=47080551

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182043TT HRP20182043T8 (hr) 2011-10-31 2018-12-05 Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze

Country Status (14)

Country Link
US (2) US20150011584A1 (hr)
EP (3) EP2586436A1 (hr)
JP (1) JP6053805B2 (hr)
CN (1) CN103906511B (hr)
AU (2) AU2012331136B2 (hr)
CA (1) CA2853325C (hr)
DK (1) DK2773337T3 (hr)
ES (1) ES2701048T3 (hr)
HR (1) HRP20182043T8 (hr)
HU (1) HUE042671T2 (hr)
IL (2) IL232292A0 (hr)
PL (1) PL2773337T3 (hr)
PT (1) PT2773337T (hr)
WO (1) WO2013064579A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620363T3 (es) * 2004-12-21 2017-06-28 Musc Foundation For Research Development Composiciones y métodos para promover la cicatrización de heridas y la regeneración tisular
AU2014295030B2 (en) * 2013-07-24 2017-06-01 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
WO2015035258A1 (en) * 2013-09-06 2015-03-12 The Rockefeller University Treatment and prevention of autism and autism spectrum disorders
JP6914858B2 (ja) * 2015-06-15 2021-08-04 ラッシュ・ユニバーシティ・メディカル・センター 脳由来のPPARαリガンド
US10864192B2 (en) * 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US10111860B1 (en) * 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
EP3593822A1 (en) 2018-07-13 2020-01-15 Theranexus Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri)
FR3110393B1 (fr) 2020-05-20 2022-05-06 Grn Consulting Compose et composition pour induire une neuroprotection
FR3128872A1 (fr) 2021-11-08 2023-05-12 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Aβ42低下物質
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
WO2004091522A2 (en) 2003-04-11 2004-10-28 Myriad Genetics, Inc. Method for treating neurodegenerative disorders
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
HUP0401850A3 (en) 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
CN101991859A (zh) * 2009-10-27 2011-03-30 上海复旦复华药业有限公司 一种石杉碱甲的β-环糊精包合物及其制备方法和制剂

Also Published As

Publication number Publication date
HUE042671T2 (hu) 2019-07-29
IL270748A (en) 2020-01-30
EP2773337A1 (en) 2014-09-10
JP2014532635A (ja) 2014-12-08
AU2012331136B2 (en) 2017-06-29
HRP20182043T8 (hr) 2019-06-14
AU2017228472A1 (en) 2017-10-05
EP3446688A1 (en) 2019-02-27
AU2017228472B2 (en) 2019-07-11
EP2773337B1 (en) 2018-09-19
WO2013064579A1 (en) 2013-05-10
EP2586436A1 (en) 2013-05-01
AU2012331136A1 (en) 2014-05-01
PL2773337T3 (pl) 2019-04-30
IL270748B (en) 2021-10-31
CA2853325A1 (en) 2013-05-10
ES2701048T3 (es) 2019-02-20
US20180177773A1 (en) 2018-06-28
JP6053805B2 (ja) 2016-12-27
CN103906511A (zh) 2014-07-02
PT2773337T (pt) 2018-12-20
CN103906511B (zh) 2016-04-06
US10765670B2 (en) 2020-09-08
CA2853325C (en) 2021-08-24
DK2773337T3 (en) 2018-12-10
US20150011584A1 (en) 2015-01-08
IL232292A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
IL270748B (en) Preparations containing a substance with anticoxinic activity and their use to increase the activity of acetylcholinesterase inhibitors
EP2673286A4 (en) THERAPEUTIC COMPOUNDS
EP2773637A4 (en) BENZOLSULFONAMIDE COMPOUNDS AND THEIR USE AS MEDICAMENTS
GB201114212D0 (en) Therapeutic agents
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
IL232530B (en) A combination of factors for cancer treatment
AP3849A (en) Use of inhibitors of the activity or function of pi3k
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
GB201119401D0 (en) Therapeutic agents
HK1198812A1 (en) Treatment of rhinitis
SG11201401287SA (en) Methods of treating liver conditions using notch2 antagonists
IL228719A0 (en) parp inhibitors for the treatment of cipn
PL3287131T3 (pl) Terapeutyczne zastosowania ektoiny
IL229081A0 (en) Isazolines as therapeutic agents
PL2723344T3 (pl) Złożony środek leczniczy zawierający monoterpen
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
HK1199832A1 (en) Combination therapy using ribavirin as eif4e inhibitor eif4e
EP2750508A4 (en) COMPOUNDS AND THERAPEUTIC METHODS
HK1193053A1 (zh) 過敏性鼻炎的治療劑
SG11201402226PA (en) Therapeutic agent for arthrosis
IL231143A0 (en) Treatment of rhinitis
EP2697382A4 (en) PREOPERATIVE USE OF METABOLIC ACTIVATION THERAPY
GB201115558D0 (en) Therapeutic agents
GB201110614D0 (en) Therapeutic agents